Characterization of patients with embolic strokes of undetermined source in the navigate esus randomized trial
Artículo

Open/ Download
Publication date
2018-06Metadata
Show full item record
Cómo citar
Kasner, Scott E.
Cómo citar
Characterization of patients with embolic strokes of undetermined source in the navigate esus randomized trial
Abstract
Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS. Aims: We aimed to describe the baseline characteristics of this large ESUS cohort to explore relationships among key subgroups. Methods: We enrolled 7213 patients at 459 sites in 31 countries. Prespecified subgroups for primary safety and efficacy analyses included age, sex, race, global region, stroke or transient ischemic attack prior to qualifying event, time to randomization, hypertension, and diabetes mellitus. Results: Mean age was 66.9 +/- 9.8 years; 24% were under 60 years. Older patients had more hypertension, coronary disease, and cancer. Strokes in older subjects were more frequently cortical and accompanied by radiographic evidence of prior infarction. Women comprised 38% of participants and were older than men. Patients from East Asia were oldest whereas those from Latin America were youngest. Patients in the Americas more frequently were on aspirin prior to the qualifying stroke. Acute cortical infarction was more common in the United States, Canada, and Western Europe, whereas prior radiographic infarctions were most common in East Asia. Approximately forty-five percent of subjects were enrolled within 30 days of the qualifying stroke, with earliest enrollments in Asia and Eastern Europe. Conclusions: NAVIGATE-ESUS is the largest randomized trial comparing antithrombotic strategies for secondary stroke prevention in patients with ESUS. The study population encompasses a broad array of patients across multiple continents and these subgroups provide ample opportunities for future research.
Patrocinador
Bayer AG
Janssen Research and Development
Canadian Stroke Prevention Intervention Network
Indexation
Artículo de publicación ISI
Identifier
URI: https://repositorio.uchile.cl/handle/2250/151780
DOI: 10.1016/j.jstrokecerebrovasdis.2018.01.027
Quote Item
Journal of stroke & cerebrovascular diseases Volumen: 27 Número: 6 Páginas: 1673-1682
Collections
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile
Related items
Showing items related by title, author, creator and subject.
-
Hidalgo, María José; Muñoz, Daniela; Balut Oyarzún, Javiera; Troncoso, Mónica; Lara, Susana; Barrios, Andrés; Parra, Patricia (Sage Publications, 2018-05-29)Stroke is an important cause of morbidity and mortality in children. Clinical presentation is diverse, and multiple risk factors have been described. The aim of this retrospective study is to describe the clinical presentation, ...
-
Minhas, Jatinder S.; Wang, Xia; Arima, Hisatomi; Bath, Philip M.; Billot, Laurent; Broderick, Joseph P.; Donnan, Geoffrey A.; Kim, Jong S.; Lavados Germain, Pablo Manuel; Lee, Tsong-Hai; Martins, Sheila Cristina Ouriques; Olavarría, Verónica V.; Pandian, Jeyaraj D.; Pontes Neto, Octavio Marques; Ricci, Stefano; Sato, Shoichiro; Sharma, Vijay K.; Thang, Nguyen H.; Wang, Ji-Guang; Woodward, Mark; Chalmers, John; Anderson, Craig S.; Robinson, Thompson G. (Karger, 2018)Background: Debate exists as to whether statin pretreatment confers an increased risk of 90-day mortality and symptomatic intracranial haemorrhage (sICH) in acute ischaemic stroke (AIS) patients treated with intravenous ...
-
Huang, Yining; Sharma, Vijay K.; Robinson, Thompson; Lindley, Richard I.; Chen, Xiaoying; Kim, Jong Sung; Lavados Germain, Pablo Manuel; Olavarría, Verónica; Arima, Hisatomi; Fuentes, Sully; Nguyen, Huy Thang; Lee, Tsong-Hai; Parsons, Mark W.; Levi, Christopher; Demchuk, Andrew M.; Bath, Philip M.W.; Broderick, Joseph P.; Donnan, Geoffrey A.; Martins, Sheila; Pontes Neto, Octavio M.; Silva, Federico; Pandian, Jeyaraj; Ricci, Stefano; Stapf, Christian; Woodward, Mark; Wang, Jiguang; Chalmers, John; Anderson, Craig S. (World Stroke Organization, 2015)RationaleControversy exists over the optimal dose of intravenous (iv) recombinant tissue plasminogen activator (rt-PA) and degree of blood pressure (BP) control in acute ischaemic stroke (AIS). Asian studies suggest low-dose ...